Portal de Periódicos da CAPES

Postinduction and Preremission Chemotherapy Alternatives for Adult AML: Three Multicenter Studies of the AML Cooperative Group

1987; Springer Nature; Linguagem: Inglês

10.1007/978-3-642-71213-5_10

0440-0607

Thomas Büchner, Wolfgang Hiddemann, D. Urbanitz, H. Kreutzmann, Georg Maschmeyer, F. Wendt, R. Kuse, Alicia M. Mohr, W. Gaßmann, H. Löffler, Kurt Straíf, H.A. Vaupel, Helmut König, Heiko Rühl, M. R. Nowrousian, H. G. Fuhr, G. Zeile, A. von Paleske, J. Schwamborn, H.H. Fülle, H. Bartels, B. Emmerich, E. Lengfelder, R. Donhuijsen‐Ant, Andy Hau Yan Ho, K. Mainzer, H. Köppler, E. Thiel, G. Middelhoff, L. Nowicki, K.‐H. Zurborn, W. Siegert, M. Planker, W. Augener, Achim Heinecke,

Synthetic Organic Chemistry Methods

Various intensive induction regimens for adult AML involving a total of 3380 patients produced a median of 60% complete remissions (CR) ranging from 47% to 72% in multicenter [2, 4, 8, 10–12, 14] and major monocenter [5, 6, 9, 13] studies. The probability of continuous CR in these studies ranges from 8% to 45% (median, 24%) at 3 years. Corresponding data projected to 5 years yield a continuous CR rate of 10%–28% (median, 21%). No clear correlation has been found between CR duration and the type of induction or postinduction treatment. In particular, the role of consolidation and long-term maintenance therapy has remained controversial.